ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.132,85
-0,44%
S&P 500
5.807,23
-0,34%
Dow Jones
42.117,23
0,43%
Euro vs US Dollar
1,02174
-0,26%
Bitcoin
91.836,38
-2,81%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. KalVista Pharmaceuticals Inc (KALV)

  7. KalVista Pharmaceuticals Inc (KALV) News

KALV

KalVista Pharmaceuticals (KALV)

KalVista Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:KALV
DatumZeitQuelleÜberschriftSymbolFirma
08/01/202512h30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
16/12/202413h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
16/12/202413h00Business WireKalVista Appoints Jeb Ledell as Chief Operating OfficerNASDAQ:KALVKalVista Pharmaceuticals Inc
10/12/202403h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
05/12/202422h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
05/12/202422h07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KALVKalVista Pharmaceuticals Inc
05/12/202412h30Business WireKalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational UpdateNASDAQ:KALVKalVista Pharmaceuticals Inc
04/12/202412h30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
28/11/202402h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
28/11/202402h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
26/11/202422h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
26/11/202422h39Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
26/11/202413h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
26/11/202413h00Business WireKalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of DirectorsNASDAQ:KALVKalVista Pharmaceuticals Inc
20/11/202401h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
20/11/202401h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
20/11/202401h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
14/11/202421h57Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:KALVKalVista Pharmaceuticals Inc
14/11/202418h02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:KALVKalVista Pharmaceuticals Inc
13/11/202418h54Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:KALVKalVista Pharmaceuticals Inc
12/11/202415h31Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:KALVKalVista Pharmaceuticals Inc
12/11/202412h30Business WireKalVista Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:KALVKalVista Pharmaceuticals Inc
07/11/202420h34Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:KALVKalVista Pharmaceuticals Inc
05/11/202412h30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
04/11/202422h40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
04/11/202413h05Business WireKalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 MillionNASDAQ:KALVKalVista Pharmaceuticals Inc
04/11/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
04/11/202413h00Business WireKalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare TrustNASDAQ:KALVKalVista Pharmaceuticals Inc
28/10/202411h30Business WireKalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and ImmunologyNASDAQ:KALVKalVista Pharmaceuticals Inc
18/10/202412h30Business WireKalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)NASDAQ:KALVKalVista Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:KALV

Kürzlich von Ihnen besucht

TSXV
BOL
Bold Ventures
LSE
0M1O
Xpo Logistics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten